^
    Back
    Association details:
    Biomarker:BCR-ABL1 F317I
    Cancer:Acute Lymphocytic Leukemia
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Regimens for relapsed or refractory Ph-positive ALL…Treatment options based on BCR-ABL1 mutation profile…Dasatinib…Contraindicated mutations...T315I/A, F317L/V/I/C, or V299L
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    ASH 2018
    Title:

    Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    Excerpt:
    DNA from 64 pts with newly diagnosed Ph+ ALL treated with hyper-CVAD plus a TKI....Of the 18 pts who relapsed...Clonal resistance mutations were detected at relapse in 9 pts (64% of sequenced samples): T315I in 6 pts, and F317I, V229L and V338G in 1 pt each (all in pts treated with dasatinib, except V338G in pt on imatinib).
    DOI:
    10.1182/blood-2018-99-115369